CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishWhereas experimental studies showed that in healthy trained subjects, the phosphodiesterase-5 inhibitor (PDE-5i) sildenafil improves exercise capacity in hypoxia and not in normoxia, no studies on the effects of the long half-life PDE-5i tadalafil exist. In order to evaluate whether tadalafil influences functional parameters and performance during a maximal exercise test in normoxia, we studied 14 healthy male athletes in a double-blind cross-over protocol. Each athlete performed two tests on a cycle ergometer, both after placebo or tadalafil (at therapeutic dose: 20 mg) administration. Oxygen consumption ((V) over dot O-2), blood lactate, respiratory exchange ratio, rate of perceived exertion, arterial blood pressure (BP), heart frequency (HR) and oxygen pulse ((V) over dot O-2/HR) were evaluated before exercise, at individual ventilatory and anaerobic thresholds (IVT and IAT), at (V) over dot O-2max and during recovery. Compared to placebo, a single tadalafil administration significantly reduced systolic BP before and after exercise (p < 0.05), decreased (V) over dot O-2/HR at IVT (13.3+/-1.8 vs. 14.5+/-2.1 mL.beat(-1); p = 0.03), but did not modify individual (V) over dot O-2max, IVT, or IAT. In healthy athletes, 20 mg of tadalafil does not substantially influence physical fitness-related parameters, exercise tolerance, and cardiopulmonary responses to maximal exercise in normoxia; it remains to be verified if higher doses/prolonged use influence health and/or sport performance in field conditions.
Di Luigi L., B.C. (2008). The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' VO2max, aerobic, and anaerobic thresholds in normoxia. INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 29(2), 110-115.
| Tipologia: | Articolo su rivista | |
| Citazione: | Di Luigi L., B.C. (2008). The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' VO2max, aerobic, and anaerobic thresholds in normoxia. INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 29(2), 110-115. | |
| IF: | Con Impact Factor ISI | |
| Lingua: | English | |
| Settore Scientifico Disciplinare: | Settore MED/09 - Medicina Interna Settore MED/13 - Endocrinologia | |
| Revisione (peer review): | Sì, ma tipo non specificato | |
| Tipo: | Articolo | |
| Rilevanza: | Rilevanza internazionale | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1055/s-2007-965131 | |
| Stato di pubblicazione: | Pubblicato | |
| Data di pubblicazione: | 2008 | |
| Titolo: | The long-acting phosphodiesterase inhibitor tadalafil does not influence athletes' VO2max, aerobic, and anaerobic thresholds in normoxia | |
| Autori: | ||
| Autori: | Di Luigi L., Baldari C., Pigozzi F., Emerenziani G.P., Gallotta M.C., Iellamo F., Ciminelli E., Sgro P., Romanelli F., Lenzi A., Guidetti L. | |
| Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
Copyright © 2021